Japan Hospice Holdings Inc. increased revenue and operating profit in the interim period of fiscal 2026 ending December, driven by the expansion of its home hospice business. However, the impact of the medical fee revision means that its full-year earnings outlook remains undetermined.
The latest earnings announcement was made on 14 August 2026. In its earnings report for the interim period of fiscal 2026 ending December, revenue rose 13.6% year on year to ¥7.6 billion, while operating profit increased 85.8% to ¥500 million, showing a substantial improvement. The main factor was the expansion of the home hospice business, while the impact of the medical fee revision has affected revenue since June, leaving the full-year earnings forecast undetermined.
The latest performance trends and summary highlights indicate that profitability has deteriorated over the past 12 quarters. There are also views that operating and net profit margins have declined, along with ROE and ROA. The equity ratio has remained below 30%, while interest-bearing debt appears to be trending upward, and EPS has also been noted as weak year on year.
Going forward, the focus is expected to be on whether the profitability improvement from the expansion of the home hospice business can continue and when the impact of the medical fee revision will begin to recover. Analyst estimates and the market reaction are covered through references to information sources in a separate section.
Other information includes selected stock metrics, such as the company forecast PER and actual PBR, as well as company information. Readers tracking figures directly relevant to investment decisions should review the earnings report summary together with trends in the financial indicators.